Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
Add more filters










Publication year range
2.
J Thromb Haemost ; 22(6): 1583-1590, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38453024

ABSTRACT

BACKGROUND: There are very few large population-based studies studying mental health in persons with von Willebrand disease (PwVWD). OBJECTIVES: We aim to assess prevalence of depression and anxiety in PwVWD over a period of 20 years and identify bleeding symptoms that may be more likely associated with depression and anxiety in PwVWD. METHODS: This is a retrospective cohort study using a deidentified national dataset from 1118 hospitals with 176 million patients. Cases were defined as patients aged 0-110 years, both male and female, with von Willebrand disease (VWD), without hemophilia. Controls were defined as patients aged 0-110 years, both male and female, without VWD or hemophilia. We compared rates of depression and anxiety in cases and controls and by type of bleeding symptoms. RESULTS: We identified 66 367 PwVWD and 183 890 766 controls. The prevalence of depression (23.12% vs 8.62%; p ≤ .00093; relative risk = 2.68) and anxiety (32.90% vs 12.29%; p ≤ .00093; relative risk = 2.68) was higher in PwVWD. Most of the bleeding symptoms were associated with higher rates of depression and anxiety in PwVWD with the highest rates with abnormal uterine bleeding, hematemesis, hemoptysis, hematuria, and melena. CONCLUSION: Our study shows that mental health disorders in PwVWD are a significant health burden, and that burden is increased with documented bleeding symptoms. It is important that primary care physicians and hematologists caring for this population recognize this increased risk and appropriately screen and refer to mental health professionals.


Subject(s)
Anxiety , Databases, Factual , Depression , Mental Health , von Willebrand Diseases , Humans , Female , Male , United States/epidemiology , Middle Aged , Adult , Prevalence , Retrospective Studies , von Willebrand Diseases/epidemiology , von Willebrand Diseases/complications , Adolescent , Aged , Depression/epidemiology , Young Adult , Child , Child, Preschool , Anxiety/epidemiology , Aged, 80 and over , Infant , Infant, Newborn , Hemorrhage/epidemiology , Risk Factors
3.
J Thromb Haemost ; 21(7): 1741-1743, 2023 07.
Article in English | MEDLINE | ID: mdl-37028651

ABSTRACT

The United States Supreme Court's ruling to overturn Roe v. Wade has potential grave implications, impacting access to reproductive healthcare for women across the country. Similarly, women and adolescent girls with bleeding disorders need access to high-quality reproductive health care because there is a significant risk of bleeding complications in these patients. Treatment decisions need to be made by patients and treating physicians and not as a consequence of political ideology. Women including those with bleeding disorders should be given the autonomy to make their own reproductive health decisions.


Subject(s)
Abortion, Legal , Supreme Court Decisions , Pregnancy , Female , Humans , United States , Adolescent , Patient Acceptance of Health Care
4.
Res Pract Thromb Haemost ; 6(3): e12708, 2022 Mar.
Article in English | MEDLINE | ID: mdl-35615754

ABSTRACT

The thrombotic microangiopathies (TMAs) are a heterogenous group of disorders with distinct pathophysiologies that cause occlusive microvascular or macrovascular thrombosis, and are characterized by microangiopathic hemolytic anemia, thrombocytopenia, and/or end-organ ischemia. TMAs are associated with significant morbidity and mortality, and data on the management of certain TMAs are often lacking. The nomenclature, classification, and management of various TMAs is constantly evolving as we learn more about these rare syndromes. Thorough clinical and laboratory evaluation is essential to distinguish various TMAs and arrive at an accurate diagnosis, which is key for appropriate management. In this illustrated review, we focus on thrombotic thrombocytopenic purpura (TTP), Shiga toxin-associated hemolytic uremic syndrome, complement-mediated hemolytic uremic syndrome, hematopoietic cell transplant-associated TMA, and drug-induced TMA, and describe their incidence, pathophysiology, diagnosis, and management. We also highlight emerging complement-directed therapies under investigation for the management of complement-mediated TMAs.

6.
Haemophilia ; 28(4): 671-678, 2022 Jul.
Article in English | MEDLINE | ID: mdl-35416396

ABSTRACT

INTRODUCTION: Persons with haemophilia(PWH) have been shown to have low bone mineral density likely the result of prolonged immobility, recurrent hemarthrosis, decreased weight bearing, lower physical activity level and obesity. Bone health has been poorly characterized in haemophilia carriers (HC) and persons with von Willebrand disease (PWvWD). AIM: To estimate the prevalence of osteoporosis, osteoarthritis and bone fractures in HC and PWvWD and identify risk factors for poor bone health. METHODS: This is a retrospective study using a population level, commercial database - Explorys (IBM Watson Health, Cleveland, USA). We compared prevalence rates of osteoporosis, osteoarthritis and fractures among cases (HC or PWvWD) and controls (general population without an underlying bleeding disorder) from 1999 to 2020. Prevalence of common risk factors for poor bone health were compared among cases and controls. RESULTS: Among 72,917,850 active persons in the database, we identified 940 women with the diagnosis of HC and 19,580 PWvWD. Among HC and PWvWD, prevalence of osteoporosis, osteoarthritis and fractures were significantly higher in cases, when compared to controls. In HC, the prevalence of vitamin D deficiency, obesity, hypothyroidism, smoking, diabetes mellitus, hypocalcaemia, corticosteroid use, malignancy, renal failure and Nonsteroidal anti-inflammatory drugs (NSAID) use were significantly higher among the cases. In PWvWD, the prevalence of risk factors was significantly higher in cases when compared to controls. CONCLUSION: The prevalence of osteoporosis, osteoarthritis and fractures is significantly higher among HC and PWvWD. This data highlights the importance of screening patients for risk factors for poor bone health and provide education to prevent these complications.


Subject(s)
Hemophilia A , Osteoarthritis , Osteoporosis , von Willebrand Diseases , Bone Density , Female , Hemophilia A/complications , Hemophilia A/epidemiology , Humans , Obesity/complications , Osteoarthritis/complications , Osteoarthritis/epidemiology , Osteoporosis/complications , Osteoporosis/epidemiology , Retrospective Studies , Risk Factors , von Willebrand Diseases/complications , von Willebrand Diseases/epidemiology
7.
Sci Rep ; 11(1): 4654, 2021 02 25.
Article in English | MEDLINE | ID: mdl-33633315

ABSTRACT

Wiskott Aldrich syndrome (WAS) is a rare disease and hematopoietic stem cell transplant (HCT) is considered the treatment modality of choice for WAS. We conducted a cross-sectional analysis on the KIDS' pediatric inpatient database and compared hospitalization rates, complications and healthcare utilizations in the transplant and non-transplant arms. Of the 383 pediatric admissions with diagnosis of WAS between 2006-2012, 114 underwent transplant and 269 did not. The non-transplant arm included older children, female patients and more African Americans. Death rates, income and payer source were similar in both arms, however the total charge for each admission was higher in the transplant arm. Emergency room visits were similar but non-elective admissions were more in the non-transplant arm. Length of stay was prolonged in the transplant arm. When comparing morbidities, lymphomas, ulcerative colitis and autoimmune complications of WAS were seen only in the non-transplant arm. Our study shows that transplant is the largest contributor to healthcare utilization in WAS patients. We identified healthcare disparities based on race and socioeconomic status and found that this rare disease is being appropriately directed to centers with HCT expertise. We noted a change in practice moving away from splenectomy in WAS patients.


Subject(s)
Healthcare Disparities , Hematopoietic Stem Cell Transplantation , Wiskott-Aldrich Syndrome/therapy , Child, Preschool , Female , Hospital Mortality , Humans , Male , Population Groups , Social Class , Wiskott-Aldrich Syndrome/complications , Wiskott-Aldrich Syndrome/mortality
8.
Thromb Res ; 192: 40-51, 2020 08.
Article in English | MEDLINE | ID: mdl-32450447

ABSTRACT

Estrogen, in the clinical setting is used primarily for contraception and hormone replacement therapy. It has been well established that estrogen increases the risk of both arterial and venous thrombosis. While estrogen is known to induce a prothrombotic milieu through various effects on the hemostatic pathways, the exact molecular mechanism leading to those effects is not known. The most common clinical presentation of estrogen-related thrombosis is venous thromboembolism (VTE) of the deep veins of the legs or pulmonary vessels, usually within the first few months of use. Estrogen has also been associated with increased risk of "unusual site" thromboses, as well as arterial thrombosis. Women at high-risk of thrombosis need careful evaluation and counseling for contraception, pregnancy, menopausal hormonal therapy and other estrogen-related conditions or treatments in order to lower the risk of thromboses. We review the most recent evidence on management of high-estrogen states in women at high-risk of thrombosis, as well as emerging data on unique populations such as transgender women. More studies are needed to better understand the pathophysiology of hormone-related thrombosis, as well as more comprehensive techniques to stratify risks for thrombosis so as to enable tailoring of recommendations for each individual.


Subject(s)
Thrombosis , Venous Thromboembolism , Venous Thrombosis , Contraception , Estrogen Replacement Therapy/adverse effects , Estrogens/adverse effects , Female , Humans , Risk Factors , Venous Thromboembolism/chemically induced
9.
Thromb Res ; 187: 103-112, 2020 03.
Article in English | MEDLINE | ID: mdl-31981840

ABSTRACT

Central venous catheters (CVC) have revolutionized the care of patients requiring long-term venous access. With increasing use of CVCs, the incidence of catheter-related thrombosis (CRT) has been on the rise. CRT constitutes 10% of all deep venous thromboses (DVT) in adults and 50-80% of all DVTs among children. The incidence of CRT varies significantly based on patient characteristics, catheter-related factors and the steps involved in the process of catheter insertion. Multiple risk factors have been associated with a higher risk of CRT, including older age, hospitalization, CVC insertion in the subclavian vein, left-sided CVC insertion, longer duration of catheter, catheter-to-vein ratio > 0.45, and type of CVC. A majority of patients with CRT are asymptomatic. Duplex ultrasound is the initial diagnostic modality of choice, though other modalities like CT angiography and MRV may be necessary for certain CRT locations. Current guidelines recommend maintaining a catheter unless nonfunctional or unneeded, in addition to systemic anticoagulation. Data guiding anticoagulant management specific to upper extremity VTE is lacking, and practice is mostly extrapolated from data on lower extremities. Further studies are required to establish evidence-based guidelines in the management of adults and children with CRT, and in particular the role of direct oral anticoagulants. In this review, we describe the knowledge gaps that exist in multiple aspects of CRT and the need for large collaborative studies to improve the care of patients with CRT.


Subject(s)
Catheterization, Central Venous , Central Venous Catheters , Upper Extremity Deep Vein Thrombosis , Venous Thrombosis , Adult , Aged , Anticoagulants , Catheterization, Central Venous/adverse effects , Central Venous Catheters/adverse effects , Child , Humans , Risk Factors , Upper Extremity Deep Vein Thrombosis/diagnosis , Upper Extremity Deep Vein Thrombosis/epidemiology , Upper Extremity Deep Vein Thrombosis/etiology
10.
J Pediatr Hematol Oncol ; 40(2): e73-e76, 2018 03.
Article in English | MEDLINE | ID: mdl-29200147

ABSTRACT

Deep venous thrombosis (DVT) has been previously reported in children with methicillin-resistant Staphylococcus aureus (MRSA). This study reviews our institutional experience by evaluating characteristics and outcomes of children with DVT and staphylococcal infections. Retrospective clinical data from 16 pediatric patients with DVT and staphylococcal infections over a 5-year period was obtained via medical record abstraction. Sixteen patients with a median age at diagnosis of 8 years were included. The most common infection encountered was osteomyelitis (56%). The most common isolated organism was MRSA (63%). Central venous catheters were present in 50% of cases. All patients received anticoagulation with low molecular weight heparin except 1 patient with superficial venous thrombosis who was managed conservatively. Fifty percent of patients had complete resolution of DVT by the end of treatment, 25% of the patients had early disappearance of the thrombus at 7 to 10 days. Only 2 patients (12.5%) had persistent thrombus at 6 months. Staphylococcal infections may increase the risk of DVT in children. Therefore, a high index of suspicion for DVT is warranted in children with Staphylococcal infections (particularly MRSA) to promptly diagnose, treat and minimize complications. Prophylactic anticoagulation in presence of staphylococcal infection, particularly MRSA, may be considered in future studies.


Subject(s)
Staphylococcal Infections/complications , Venous Thrombosis/etiology , Adolescent , Child , Child, Preschool , Female , Humans , Infant , Male , Retrospective Studies , Venous Thrombosis/epidemiology
11.
Curr Neuropharmacol ; 16(7): 1045-1058, 2018.
Article in English | MEDLINE | ID: mdl-29189165

ABSTRACT

BACKGROUND: Medulloblastoma is the most common malignant brain tumor in children, currently treated uniformly based on histopathology and clinico-radiological risk stratification leading to unpredictable relapses and therapeutic failures. Identification of molecular subgroups have thrown light on the reasons for these and now reveals clues to profile molecularly based personalized therapy against these tumors. METHODS: Research and online contents were evaluated for pediatric medulloblastoma which included latest information on the molecular subgroups and their clinical relevance and update on efforts to translate them into clinics. RESULTS: Scientific endeavors over the last decade have clearly identified four molecular variants (WNT, SHH, Group 3, and Group 4) and their demographic, genomic, and epigenetic profile. Latest revelations include significant heterogeneity within these subgroups and 12 different subtypes of MB are now identified with disparate outcomes and biology. These findings have important implications for stratification and profiling future clinical trials against these formidable tumors. CONCLUSION: With the continued outpouring of genomic/epigenomic data of these molecular subgroups and evolution of further subtypes in each subgroup, the challenge lies in comprehensive evaluation of these informations. Current and future endeavors are now needed to profile personalized therapy for each child based on the molecular risk stratification of medulloblastoma, with a hope to improve survival outcome and reduce relapses.


Subject(s)
Brain Neoplasms/therapy , Medulloblastoma/therapy , Brain Neoplasms/genetics , Brain Neoplasms/metabolism , Child , Humans , Medulloblastoma/genetics , Medulloblastoma/metabolism
12.
J Pediatr Surg ; 47(7): E5-8, 2012 07.
Article in English | MEDLINE | ID: mdl-22813829

ABSTRACT

Penile abnormalities such as epispadias, diphallia, asymmetry, and aphallia have been reported with cloacal exstrophy. The presence of intravesical phallus with cloacal exstrophy is presented with a review of literature.


Subject(s)
Abnormalities, Multiple/diagnosis , Anus, Imperforate/diagnosis , Bladder Exstrophy/diagnosis , Colon/abnormalities , Hernia, Umbilical/diagnosis , Penis/abnormalities , Fatal Outcome , Humans , Infant, Newborn , Male
SELECTION OF CITATIONS
SEARCH DETAIL
...